Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
Commentary|Videos|December 17, 2025
Response Rates with Pumitamig Plus Chemo Suggest Synergistic Effect
Author(s)Peter Schmid, MD, PhD
Fact checked by: Paige Britt
A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for advanced cancer treatments.
Advertisement
Watch the first part of our interview with Peter Schmid, MD, PhD,
In the second part of our interview with Schmid, Barts Cancer Institute, London, England, he details the safety and efficacy results of pumitamig plus chemotherapy in patients with triple negative breast cancer.
Advertisement
Related to this article
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
4
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
5